Aspectos y consideraciones generales en la enfermedad inflamatoria intestinal durante la pandemia por COVID-19

So far, available evidence suggests that patients with inflammatory bowel disease (IBD) are not at greater risk for developing COVID-19 infection. In regard to patients with IBD remission: 5-aminosalycylates (5-ASAs) do not increase the risk for infection and should be continued. There is no need to...

Descripción completa

Detalles Bibliográficos
Autores principales: de León-Rendón, J.L., Hurtado-Salazar, C., Yamamoto-Furusho, J.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245301/
https://www.ncbi.nlm.nih.gov/pubmed/32536480
http://dx.doi.org/10.1016/j.rgmx.2020.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245301/
https://www.ncbi.nlm.nih.gov/pubmed/32536480
http://dx.doi.org/10.1016/j.rgmx.2020.05.001

Ejemplares similares